Nektar Therapeutics (NKTR) and TrialNet said Monday that they agreed to collaborate to evaluate Nektar's drug, rezpegaldesleukin, in patients with new onset stage 3 type 1 diabetes mellitus.
Under the agreement, the companies said TrialNet will conduct a phase 2 trial involving about 70 adults and children to assess the safety and potential efficacy of the treatment, while Nektar will provide rezpegaldesleukin and support the study with pharmacokinetic analyses and other evaluations.
The companies said Nektar will retain all rights to the drug under the agreement.
The study will measure the drug's efficacy using a mixed meal tolerance test to assess C-peptide levels over a 12-month period, which includes a 6-month treatment phase and a 6-month follow-up, the companies said, adding secondary objectives include evaluating pharmacokinetics, pharmacodynamics, HbA1c levels, and insulin requirements.
Financial details of the partnership were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.